[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.122.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 27, 2000

Glycoprotein Inhibitors and Fibrinolysis in Myocardial Infarction

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(24):3124-3125. doi:10.1001/jama.284.24.3123

To the Editor: Drs Bhatt and Topol discussed the role of glycoprotein (Gp) IIb/IIIa inhibitors in acute coronary syndromes,1 but did not comment on the use of these agents in patients who have received fibrinolytic therapy. It is not uncommon for patients who have received such treatment to require further acute intervention. Are there any data about the risk-benefit ratio of Gp IIb/IIIa agents in patients who may subsequently require urgent angioplasty following failed fibrinolytic therapy?

First Page Preview View Large
First page PDF preview
First page PDF preview
×